PH12017501769A1 - Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone - Google Patents
Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidoneInfo
- Publication number
- PH12017501769A1 PH12017501769A1 PH12017501769A PH12017501769A PH12017501769A1 PH 12017501769 A1 PH12017501769 A1 PH 12017501769A1 PH 12017501769 A PH12017501769 A PH 12017501769A PH 12017501769 A PH12017501769 A PH 12017501769A PH 12017501769 A1 PH12017501769 A1 PH 12017501769A1
- Authority
- PH
- Philippines
- Prior art keywords
- chlorthalidone
- losartan
- amlodipine
- complex formulation
- pharmaceutical complex
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
The present invention provides a pharmaceutical complex formulation comprising a first mixture including amlodipine and chlorthalidone and a second mixture including losartan, which has an improved dissolution and stability. The complex formulation according to the present invention may achieve improved preventive or therapeutic effects for cardiovascular diseases by actuating different mechanism of amlodipine, losartan and chlorthalidone, and exhibits high dissolution rates of amlodipine, losartan and chlorthalidone and improved storage stability, due to the minimized drug interactions, and therefore, it is useful in the fields of pharmaceuticals and medicine.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150045645A KR101914930B1 (en) | 2015-03-31 | 2015-03-31 | Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone |
PCT/KR2016/002437 WO2016159535A1 (en) | 2015-03-31 | 2016-03-11 | Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone |
Publications (2)
Publication Number | Publication Date |
---|---|
PH12017501769A1 true PH12017501769A1 (en) | 2018-03-19 |
PH12017501769B1 PH12017501769B1 (en) | 2018-03-19 |
Family
ID=57007292
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PH12017501769A PH12017501769B1 (en) | 2015-03-31 | 2017-09-26 | Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone |
Country Status (11)
Country | Link |
---|---|
KR (1) | KR101914930B1 (en) |
CN (1) | CN108289850B (en) |
AR (1) | AR105758A1 (en) |
JO (1) | JO3461B1 (en) |
MX (1) | MX2017012459A (en) |
MY (1) | MY190016A (en) |
PH (1) | PH12017501769B1 (en) |
RU (1) | RU2713883C2 (en) |
TW (1) | TWI714560B (en) |
UY (1) | UY36595A (en) |
WO (1) | WO2016159535A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101910902B1 (en) * | 2016-11-03 | 2018-10-24 | 한미약품 주식회사 | Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone |
KR20180053044A (en) * | 2016-11-11 | 2018-05-21 | 주식회사유한양행 | A pharmaceutical composition in a monolithic matrix tablet form comprising chlorthalidone or its salt and amlodipine or its salt and a process for preparing the same |
KR20200143914A (en) * | 2019-06-17 | 2020-12-28 | 주식회사유한양행 | A pharmaceutical composition in a multi-layered tablet form comprising amlodipine or its salt and chlorthalidone its salt |
KR20210074428A (en) | 2019-12-11 | 2021-06-22 | 한미약품 주식회사 | Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone |
CN115666564A (en) * | 2020-06-09 | 2023-01-31 | 韩美药品株式会社 | Pharmaceutical combination preparation for preventing or treating cardiovascular system diseases comprising amlodipine, losartan and chlorthalidone in a single-layered tablet |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5138069A (en) | 1986-07-11 | 1992-08-11 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles |
CA2179067A1 (en) | 1993-12-23 | 1995-06-29 | Gordon Creston Campbell, Jr. | Polymorphs of losartan and the process for the preparation of form ii of losartan |
KR100452491B1 (en) | 2001-03-29 | 2004-10-12 | 한미약품 주식회사 | A novel crystalline amlodipine camsylate and a preparing method thereof |
US20030152622A1 (en) * | 2001-10-25 | 2003-08-14 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral diuretic |
EG24716A (en) * | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
CA2532450C (en) * | 2003-07-16 | 2012-09-11 | Boehringer Ingelheim International Gmbh | Chlorthalidone combinations |
US20070237815A1 (en) * | 2006-04-06 | 2007-10-11 | Lawrence Solomon | Dosage forms and methods comprising amlodipine and chlorthalidone |
KR101247583B1 (en) * | 2006-12-08 | 2013-03-26 | 한미사이언스 주식회사 | Pharmaceutical composition comprising amlodipine or a pharmaceutically acceptable salt thereof and losartan or a pharmaceutically acceptable salt thereof |
KR20090057538A (en) * | 2007-12-03 | 2009-06-08 | 박사룡 | A composition for treating hypertension comprising angiotensin ii antagonist, calsium andtagonist and diuretics |
WO2009084040A1 (en) * | 2007-12-28 | 2009-07-09 | Rubicon Research Private Limited | Once a day formulation of angiotensin receptor blockers |
AU2009338267B2 (en) | 2009-01-23 | 2014-09-18 | Hanmi Science Co., Ltd. | Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same |
KR101907881B1 (en) * | 2011-12-30 | 2018-12-11 | 한미약품 주식회사 | Fixed dose combination formulation comprising losartan, amlodipine and hydrochlorothiazide |
KR101392364B1 (en) * | 2012-04-17 | 2014-05-07 | 한국유나이티드제약 주식회사 | Pharmaceutical composition comprising amlodipine and losartan having an improved stability |
-
2015
- 2015-03-31 KR KR1020150045645A patent/KR101914930B1/en active IP Right Grant
-
2016
- 2016-03-11 CN CN201680020057.5A patent/CN108289850B/en active Active
- 2016-03-11 MY MYPI2017703447A patent/MY190016A/en unknown
- 2016-03-11 MX MX2017012459A patent/MX2017012459A/en unknown
- 2016-03-11 WO PCT/KR2016/002437 patent/WO2016159535A1/en active Application Filing
- 2016-03-11 RU RU2017134562A patent/RU2713883C2/en active
- 2016-03-18 TW TW105108523A patent/TWI714560B/en not_active IP Right Cessation
- 2016-03-27 JO JOP/2016/0058A patent/JO3461B1/en active
- 2016-03-29 AR ARP160100825A patent/AR105758A1/en unknown
- 2016-03-30 UY UY0001036595A patent/UY36595A/en not_active Application Discontinuation
-
2017
- 2017-09-26 PH PH12017501769A patent/PH12017501769B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
JO3461B1 (en) | 2020-07-05 |
KR101914930B1 (en) | 2018-11-05 |
AR105758A1 (en) | 2017-11-08 |
TW201639563A (en) | 2016-11-16 |
WO2016159535A1 (en) | 2016-10-06 |
CN108289850B (en) | 2021-04-09 |
PH12017501769B1 (en) | 2018-03-19 |
MX2017012459A (en) | 2018-01-30 |
RU2017134562A (en) | 2019-04-04 |
TWI714560B (en) | 2021-01-01 |
RU2713883C2 (en) | 2020-02-10 |
RU2017134562A3 (en) | 2019-08-15 |
MY190016A (en) | 2022-03-22 |
UY36595A (en) | 2016-10-31 |
CN108289850A (en) | 2018-07-17 |
KR20160117055A (en) | 2016-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017501769A1 (en) | Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone | |
CY1123649T1 (en) | IMIDAZOLINE DERIVATIVES, METHODS OF THEIR PREPARATION AND THEIR APPLICATIONS IN MEDICINE | |
PH12018500591A1 (en) | Heterocyclic compounds and uses thereof | |
CR20160275A (en) | DERIVATIVES OF SULPHAMOYLPYRROLAMIDE AND USE AS A MEDICINAL PRODUCT FOR THE TREATMENT OF HEPATITIS B | |
EA033544B1 (en) | Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors | |
MX2018004175A (en) | Oxa spiro derivative, preparation method therefor, and applications thereof in medicines. | |
TN2015000278A1 (en) | Autotaxin inhibitors | |
EA033343B1 (en) | Compounds inhibiting rip2 kinase, pharmaceutical composition based thereon and use thereof for the treatment of diseases mediated by rip2 kinase | |
TN2017000529A1 (en) | New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them | |
EA201591371A1 (en) | Pyridine derivatives as easily degraded inhibitors ROCK | |
IN2014DN06501A (en) | ||
PH12016500420A1 (en) | Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt | |
MX357780B (en) | Polycyclic derivatives, preparation method and medical uses thereof. | |
MX2015009269A (en) | Pharmaceutical compositions comprising nitroxyl donors. | |
CO7160008A2 (en) | Derivatives of estra- 1,3,5 (10), 3-substituted 16-tetraene, methods for their preparation, pharmaceutical preparations containing them, as well as their use for the preparation of medicines | |
MA39765A (en) | Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use | |
MX2018000546A (en) | Pharmaceutical composition containing celecoxib and tramadol. | |
MX2017003561A (en) | Compositions and methods for cannabinoid coatings for use in drug delivery. | |
PH12019500778A1 (en) | Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone | |
MX2017013636A (en) | Tamper-resistant fixed dose combination providing fast release of two drugs from different particles. | |
WO2016040462A3 (en) | Formulations and methods for treatment of metabolic syndrome | |
IN2015DN02999A (en) | ||
BR112018068370A2 (en) | fixed dose pharmaceutical composition containing amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension | |
CL2017002229A1 (en) | Bace1 inhibitors. | |
MX2017013633A (en) | Tamper-resistant fixed dose combination providing fast release of two drugs from particles. |